

## Clinical Policy: Elranatamab-bcmm (Elrexio)

Reference Number: LA.PHAR.652

Effective Date: 12.01.23

Last Review Date: ~~12.22.25~~01-09-25

Line of Business: Medicaid

[Coding Implications](#)

[Revision Log](#)

Formatted: Spanish (Spain)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

**\*\*Please note: This policy is for medical benefit\*\***

### Description

Elranatamab-bcmm (Elrexio<sup>TM</sup>) is bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager.

### FDA Approved Indication(s)

Elrexio is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma (MM) who have received at least four prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.

This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).

### Policy/Criteria

It is the policy of Louisiana Healthcare Connections that Elrexio is **medically necessary** when the following criteria are met:

#### I. Initial Approval Criteria

##### A. Multiple Myeloma (must meet all):

1. Diagnosis of MM;
2. Prescribed by or in consultation with an oncologist or hematologist;
3. Age  $\geq$  18 years;
4. Disease is relapsed or refractory;
5. One of the following (a or b):
  - a. Member has measurable disease as evidenced by one of the following assessed within the last 30 days (i, ii, or iii):
    - i. Serum M-protein  $\geq$  0.5 g/dL;
    - ii. Urine M-protein  $\geq$  200 mg/24 h;
    - iii. Serum free light chain (FLC) assay: involved FLC level  $\geq$  10 mg/dL (100 mg/L) provided serum FLC ratio is abnormal;
  - b. Member has progressive disease, as defined by the IMWG response criteria (see *Appendix D*), assessed within 60 days following the last dose of the last anti-myeloma drug regimen received;
6. Elrexio is prescribed as monotherapy;

Formatted: German (Germany)

7. Member has received or has documented intolerance to  $\geq 4$  prior lines of therapy\* (see Appendix B for examples) that include all of the following (a, b, and c):
  - a. One proteasome inhibitor (e.g., bortezomib, Kyprolis<sup>®</sup>, Ninlaro<sup>®</sup>);
  - b. One immunomodulatory drug (e.g., ~~Revlimid<sup>®</sup>~~, ~~pomalidomide~~, ~~lenalidomide~~, ~~Pomalyst<sup>®</sup>~~, Thalomid<sup>®</sup>);
  - c. One anti-CD38 antibody (e.g., Darzalex<sup>®</sup>/Darzalex Faspro<sup>®</sup>, Sarclisa<sup>®</sup>);

*\*Prior authorization may be required*
8. Request meets one of the following (a or b):\*
  - a. Dose does not exceed one of the following (i, ii, or iii): ~~12 mg on day 1, 32 mg on day 4, 76 mg on day 8 and weekly thereafter through week 24;~~
    - i. 12 mg on day 1, 32 mg on day 4, 76 mg on day 8 and weekly thereafter through week 24;
    - ii. Week 25 through week 48: 76 mg every 2 weeks;
    - iii. Week 49 of therapy and beyond: 76 mg every 4 weeks;
  - b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

*\*Prescribed regimen must be FDA-approved or recommended by NCCN*

**Approval duration: 6-12 months**

**B. Other diagnoses/indications** (must meet 1 or 2):

- a. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255;
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to LA.PMN.53.

**II. Continued Therapy**

**A. Multiple Myeloma** (must meet all):

1. Currently receiving medication via Louisiana Healthcare Connections benefit, or documentation supports that member is currently receiving Elrexfio for a covered indication and has received this medication for at least 30 days;
2. Member is responding positively to therapy;
3. If request is for a dose increase, request meets one of the following (a or b):\*
  - a. Dose does not exceed one of the following (i, ii, or ~~iii~~):
    - i. Up to week 24 of therapy: 76 mg weekly;
    - ii. Week 25 through week 48: 76 mg every 2 weeks;
    - ~~iii. Week 49 of therapy and beyond: 76 mg every 24 weeks;~~
  - b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

*\*Prescribed regimen must be FDA-approved or recommended by NCCN*

**Approval duration: 12 months.**

**B. Other diagnoses/indications** (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255;

**CLINICAL POLICY**  
Elranatamab-bcmm



2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to [LA.PMN.53 the off-label use policy](#)  
[LA.PMN.53](#).

**III. Diagnoses/Indications for which coverage is NOT authorized:**

A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – [LA.PMN.53 for Medicaid or evidence of coverage documents](#).

**IV. Appendices/General Information**

*Appendix A: Abbreviation/Acronym Key*

BCMA: B-cell maturation antigen

FDA: Food and Drug Administration

FLC: free light chain

IMWG: International Myeloma Working Group

MM: multiple myeloma

NCCN: National Comprehensive Cancer

Network

*Appendix B: Therapeutic Alternatives*

*This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent and may require prior authorization.*

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
bortezomib/Revlimid® (lenalidomide)/dexamethasone	Varies	Varies
bortezomib/cyclophosphamide/dexamethasone	Varies	Varies
bortezomib/doxorubicin (or liposomal doxorubicin)/dexamethasone	Varies	Varies
Kyprolis® (carfilzomib) Revlimid® (lenalidomide)/dexamethasone	Varies	Varies
Kyprolis® (carfilzomib)/cyclophosphamide/dexamethasone	Varies	Varies
Kyprolis® (carfilzomib – weekly or twice weekly)/dexamethasone	Varies	Varies
Ninlaro® (ixazomib)/Revlimid® (lenalidomide)/dexamethasone	Varies	Varies
Ninlaro® (ixazomib)/dexamethasone	Varies	Varies
Ninlaro® (ixazomib)/pomalidomide/dexamethasone	Varies	Varies
bortezomib/dexamethasone	Varies	Varies
bortezomib/Thalomid® (thalidomide)/dexamethasone	Varies	Varies
cyclophosphamide/Revlimid® (lenalidomide)/dexamethasone	Varies	Varies
Revlimid® (lenalidomide)/dexamethasone	Varies	Varies
VTD-PACE (dexamethasone/Thalomid® (thalidomide)	Varies	Varies

Formatted: Spanish (Spain)

Formatted: Spanish (Spain)

Formatted: Spanish (Spain)

Formatted: Spanish (Spain)

Formatted: Spanish (Spain)

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
/cisplatin/doxorubicin/cyclophosphamide/etoposide/bortezomib)		
Revlimid® (lenalidomide)/low-dose dexamethasone	Varies	Varies
Darzalex® (daratumumab) or Darzalex Faspro™ (daratumumab/hyaluronidase-fihj)/bortezomib/melphan/prednisone	Varies	Varies
Darzalex® (daratumumab) or Darzalex Faspro™ (daratumumab/hyaluronidase-fihj)/bortezomib/dexamethasone	Varies	Varies
Darzalex® (daratumumab) or Darzalex Faspro™ (daratumumab/hyaluronidase-fihj)/Revlimid® (lenalidomide)/dexamethasone	Varies	Varies
Darzalex® (daratumumab) or Darzalex Faspro™ (daratumumab/hyaluronidase-fihj)	Varies	Varies
Darzalex® (daratumumab) or Darzalex Faspro™ (daratumumab/hyaluronidase-fihj)/pomalidomide/dexamethasone	Varies	Varies
Empliciti® (elotuzumab)/Revlimid® (lenalidomide)/dexamethasone	Varies	Varies
Empliciti® (elotuzumab)/bortezomib/dexamethasone	Varies	Varies
Empliciti® (elotuzumab)/pomalidomide/dexamethasone	Varies	Varies
bendamustine/bortezomib/dexamethasone	Varies	Varies
bendamustine/Revlimid® (lenalidomide)/dexamethasone	Varies	Varies
panobinostat/bortezomib/dexamethasone	Varies	Varies
panobinostat/Kyprolis® (carfilzomib)	Varies	Varies
panobinostat/Revlimid® (lenalidomide)/dexamethasone	Varies	Varies
pomalidomide/cyclophosphamide/dexamethasone	Varies	Varies
pomalidomide/dexamethasone	Varies	Varies
pomalidomide/bortezomib/dexamethasone	Varies	Varies
pomalidomide/Kyprolis® (carfilzomib)/dexamethasone	Varies	Varies
Sarclisa® (isatuximab-irfc)/ pomalidomide/dexamethasone	Varies	Varies

- Formatted: Spanish (Spain)
- Formatted: Spanish (Spain)
- Formatted: Spanish (Spain)
- Formatted: Spanish (Spain)
- Formatted: Spanish (Spain)

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

**Appendix C: Contraindications/Boxed Warnings**

- Contraindication(s): None
- Boxed warning(s): cytokine release syndrome, neurologic toxicity including immune effector cell-associated neurotoxicity syndrome

**Appendix D: General Information**

- The IMWG response criteria for multiple myeloma definition of progressive disease requires only one of the following:
  - Increase of 25% from lowest response value in any of the following:

**CLINICAL POLICY**  
Elranatamab-bcmm



- Serum M-component (absolute increase must be  $\geq 0.5$  g/dL), and/or
- Urine M-component (absolute increase must be  $\geq 200$  mg/24 h), and/or
- Only in patients without measurable serum and urine M-protein levels: the difference between involved and uninvolved FLC levels (absolute increase must be  $> 10$  mg/dL)
- Only in patients without measurable serum and urine M protein levels and without measurable disease by FLC levels, bone marrow plasma cell percentage irrespective of baseline status (absolute increase must be  $\geq 10\%$ )
- Appearance of a new lesion(s),  $\geq 50\%$  increase from nadir in SPD (sum of the products of the maximal perpendicular diameters of measured lesions) of  $> 1$  lesion, or  $\geq 50\%$  increase in the longest diameter of a previous lesion  $> 1$  cm in short axis;
- $\geq 50\%$  increase in circulating plasma cells (minimum of 200 cells per  $\mu$ L) if this is the only measure of disease

**V. Dosage and Administration**

Indication	Dosing Regimen	Maximum Dose
MM	Administer subcutaneously  Step-up dosing schedule: <ul style="list-style-type: none"> <li>• Day 1: 12 mg</li> <li>• Day 4: 32 mg</li> <li>• Day 8 (first treatment dose): 76 mg</li> </ul> Weekly dosing schedule: <ul style="list-style-type: none"> <li>• One week after first treatment dose and weekly thereafter through week 24: 76 mg weekly</li> </ul> Biweekly (every 2 weeks) dosing schedule: <ul style="list-style-type: none"> <li>• <u>Week 25 and every 2 weeks thereafter through week 48: 76 mg</u></li> <li>• <u>Every 4 week dosing schedule:*</u></li> <li>• <u>Week 49 and every 4 weeks thereafter: 76 mg</u></li> </ul> * <u>In patients who have maintained the response following 24 weeks of treatment at biweekly dosing schedule</u>	See dosing regimen

Formatted: Keep with next

Formatted: Normal, No bullets or numbering

**VI. Product Availability**

Injection, single-dose vials (40 mg/mL): 44 mg/1.1 mL, 76 mg/1.9 mL

**VII. References**

1. Elrexfio Prescribing Information. New York, NY: Pfizer Inc.; ~~August 2023~~ July 2025. Available at: [www.Elrexfio.com](http://www.Elrexfio.com). Accessed July ~~15, 2024~~ 09, 2025.
2. National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at: [http://www.nccn.org/professionals/drug\\_compendium](http://www.nccn.org/professionals/drug_compendium). Accessed August ~~1, 2024~~ 28, 2025.

**CLINICAL POLICY**  
**Elranatamab-bcmm**



3. National Comprehensive Cancer Network. Multiple Myeloma Version [4.2024.2.2026](https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf). Available at: [https://www.nccn.org/professionals/physician\\_gls/pdf/myeloma.pdf](https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf). Accessed August ~~1, 2024~~ [28, 2025](#).
4. Lesokhin AM, Tomasson MH, Arnulf B, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023 Aug 15. doi: 10.1038/s41591-023-02528-9.

**Coding Implications**

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J1323	Injection, elranatamab-bcmm, 1 mg

Reviews, Revisions, and Approvals	Date	LDH Approval Date
Converted corporate to local policy.	01.04.24	05.06.24
Removed inactive HCPCS code [C9399] and added HCPCS code [J1323]	07.25.24	09.26.24
Annual review: removed inactive HCPC code [J9999]; references reviewed and updated	01.09.25	<a href="#">04.07.25</a>
<a href="#">Annual review: added new 4-week dosing regimen to criteria; initial approval duration changed from 6 to 12 months; references reviewed and updated.</a>	<a href="#">12.22.25</a>	

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. LHCC makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable LHCC administrative policies and procedures.

**CLINICAL POLICY**  
Elranatamab-bcmm



This clinical policy is effective as of the date determined by LHCC. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. LHCC retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom LHCC has no control or right of control. Providers are not agents or employees of LHCC.

This clinical policy is the property of LHCC. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members, and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

©2025 Louisiana Healthcare Connections. All rights reserved. All materials are exclusively owned by Louisiana Healthcare Connections and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Louisiana Healthcare Connections. You may not alter or remove any trademark, copyright or other notice contained herein. Louisiana Healthcare Connections is a registered trademark exclusively owned by Louisiana Healthcare Connections.